PITTSBURGH--(BUSINESS WIRE)--Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with a high unmet need, today announced that Rachel L. Kopper, the company’s Director of Business Operations and Finance, has been elected National President and Board Chair of Women In Bio (WIB).
WIB is an organization of professionals committed to promoting careers, leadership, and entrepreneurship for women in the life sciences. Since its founding in 2001, WIB has established 13 chapters in the U.S. and Canada, with more than 2,000 members and programs that reach 22,000 participants. WIB programs span the career life cycle, from mentoring middle-school STEM students and young professionals to supporting executive development and governance readiness.
“We are proud of Rachel for taking on this national role in promoting career opportunities for women in the life sciences,” said Michael Bozik, M.D., President and CEO of Knopp. “Her election as national president reinforces her leadership skills as well as her commitment to strengthening our industry through diversity, inclusion, and empowerment.”
Kopper, a Knopp employee since 2007, was instrumental in founding the WIB chapter in Pittsburgh in 2012 and served as Chapter Chair in 2016. She holds a MBA from Chatham University and is a graduate of Westminster College.
“I’m honored to be chosen to represent WIB at a national level, am eager to continue advancing the organization’s important agenda, and pleased at the recognition of Pittsburgh’s leadership in strengthening career opportunities for women in the life sciences community,” Kopper said.
ABOUT KNOPP BIOSCIENCES LLC
Knopp Biosciences, based in Pittsburgh, PA, USA, is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with a high unmet need. Knopp’s clinical-stage small molecule, dexpramipexole, is entering Phase 2 clinical trials in eosinophilic asthma and Phase 3 development in hypereosinophilic syndrome. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for neonatal epileptic encephalopathy, other rare epilepsies, tinnitus, and neuropathic pain. Please visit www.knoppbio.com.
ABOUT WOMEN IN BIO (WIB)
WIB is an organization of professionals committed to promoting careers, leadership, and entrepreneurship of women in the life sciences. Each local chapter hosts numerous events throughout the year, that vary from networking events to career development, to professional education, to executive level-focused events. In addition to events, WIB hosts a Young Women In Bio program, which offers events and encouragement to middle-school aged girls, a mentorship program which provides women the chance to mentor or be mentored, and a national Boardroom Ready program through Executive Women In Bio, which has recently placed over 20 women on for-profit boards. With the support of a large national organization, WIB currently has 13 chapters across North America. As a volunteer organization, WIB offers leadership opportunities at every career stage, and a chance to expand professional networks in a supportive and inclusive environment. Please visit www.womeninbio.org.
